Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study - Abstract

BACKGROUND AND PURPOSE:To evaluate outcome in patients with Gleason 7 prostate cancer treated with iodine-125 brachytherapy at the British Columbia Cancer Agency.

MATERIALS AND METHODS: Between 20th July 1998 and 7th February 2006, 1500 patients underwent I-125 prostate brachytherapy without supplemental external beam radiation therapy. Of these, 439 had Gleason 7 disease; 362 had Gleason 3+4 and 77 had 4+3 disease. Generally, patients received 6months of androgen suppression. We compared biochemical no evidence of disease (bNED) between patients with Gleason ⩽ 6 and Gleason 7 and between Gleason 3+4 and 4+3 using the Phoenix definition of biochemical recurrence.

RESULTS: Median follow-up was 60months. Estimated 5year bNED was 97% for patients with Gleason score ⩽ 6 and 94% for patients with Gleason 7 disease (p=0.037). Estimated bNED was 95% and 94% for 3+4 and 4+3, respectively (p=0.791). There was no difference in bNED between implants achieving D90 ⩾versus< the median value (150.5Gy) or ⩾versus< 140Gy.

CONCLUSIONS: I-125 brachytherapy with 6months of ADT demonstrates excellent bNED rates in Gleason 7 disease. We found no evidence of a difference between patients with Gleason 3+4 versus 4+3 disease.

Written by:
Herbert C, Morris WJ, Keyes M, Hamm J, Lapointe V, McKenzie M, Pickles T, Spadinger I. Are you the author?
Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada.

Reference: Radiother Oncol. 2012 Feb 10. Epub ahead of print.
doi: 10.1016/j.radonc.2012.01.006

PubMed Abstract
PMID: 22326573